Intrinsiqq
⚠ Showing the latest available close (Sep 25, 2026, 24 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.
Synergy CHC Corp. logoSynergy CHC Corp.SNYR
$0.0136-20.00%
Synergy CHC Corp. logo

Synergy CHC Corp.

SNYR

$0.01

-$0.00 (-20.00%)

⊜ Compare
ProfitabilityUnprofitableGrowthModeratingCash FlowN/AValuationN/A
What stands out

The business is unprofitable at the operating level (-27.84% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.

What's changing

Revenue growth slowed to 1.3%, essentially flat. Margins also contracted 47.2pp. This is a business that needs a catalyst.

What deserves caution

ROIC dropped from 26.69% to -24.64%, capital efficiency is deteriorating. Operating margin contracted 47.2pp YoY, cost discipline may be slipping.

Price History

-99.4%

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$203K
EPS-$1.60
P/E-0.01
P/FCF—
EV/EBITDA-2.52
FCF Yield—
Div. Yield—
Net Debt/FCF—
52-Week Range
$0.01$0.03

Profitability & Returns

Revenue (TTM)

$6M

▲ +1.3% YoY

Net Income (TTM)

-$16M

▼ -680.8% YoY

Op. Margin

-186.83%

▼ -47.2pp YoY

ROIC

-32.58%

▼ -51.3pp YoY

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

-$4M

▲ +46.2% YoY

Net Debt

$27M

Cash & Equiv.

$292K

5Y CAGR: -3.1%

Continue Research

SourceComputed from the 10-Q filed 11 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 26 Sept 2026. How this is calculated.

Price from market data, last close as of 25 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.

Is Synergy CHC (SNYR) overvalued?

Synergy CHC (SNYR) trades above a two-stage DCF intrinsic value of about $-0.63 per share, so at $0.01 the stock looks overvalued (4,708.9% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.

On quality, Synergy CHC scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.

Frequently asked

What is Synergy CHC's fair value?+

Intrinsiqq's two-stage DCF estimates an intrinsic value of about $-0.63 per share for SNYR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $-0.47. At today's $0.01, that puts the stock about 4,708.9% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.

Is Synergy CHC a high-quality business?+

Synergy CHC scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -186.8% operating margin and a -32.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Is Synergy CHC a good stock to buy right now?+

That depends on valuation and quality together, not either alone. SNYR currently trades above its estimated intrinsic value and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.

Related stocks: Medicinal Chemicals & Botanical Products

Spot a number that looks wrong?

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.